<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00116142</url>
  </required_header>
  <id_info>
    <org_study_id>05-043</org_study_id>
    <nct_id>NCT00116142</nct_id>
  </id_info>
  <brief_title>Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer</brief_title>
  <official_title>Docetaxel Plus 6-month Androgen Suppression and Radiation Therapy Versus 6-month Androgen Suppression and Radiation Therapy for Patients With High Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized study is looking at the benefits of using docetaxel (chemotherapy) added to
      one of the standard treatments (radiation and hormones) for men with high-risk prostate
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiation therapy plus six months of hormone therapy is one standard way of treating men with
      high-risk prostate cancer. In this study, we want to see whether or not adding the
      chemotherapy drug docetaxel (Taxotere)will make this treatment more effective. Docetaxel has
      shown a benefit in median survival when given to men who have become resistant to hormonal
      therapy and in men who have metastatic prostate cancer (spread to other areas of the body).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if overall survival is increased</measure>
    <time_frame>2014</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if PSA doubling time is prolonged; To determine if PSA failure is decreased; To determine if cancer specific mortality is decreased</measure>
    <time_frame>2014</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Androgen Suppression Therapy and Radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel plus androgen suppression therapy and radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>60 mg/m² q 3 weeks for 3 cycle at the start of treatment followed by weekly Docetaxel at 20 mg/m² per week beginning at week one of radiation therapy and continuing for seven weeks.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androgen Hormonal Suppression and Radiation</intervention_name>
    <description>Total Androgen Ablation and external beam radiation therapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androgen Suppression Therapy and Radiation Therapy</intervention_name>
    <description>Total Androgen Ablation and External Beam Radiation Therapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven prostate cancer

          -  Clinical Tumor Category T1b, T1c, T2a and PSA greater than (&gt;) 10 or Gleason score
             equal or greater than 4+3=7 or PSA velocity &gt; 2.0 ng/ml per year and also eligible
             patients with tumor category T2c, T3a, T3b, or T4 as per 2002 AJCC guidelines. Any
             minor tertiary grade of Gleason 5; Biopsy Proven or Radiographic (erMRI Seminal
             Vesicle Invasion); Gleason = or &gt; 3+4=7 with 50% or more cores positive

          -  Negative bone scan

          -  Lymph node assessment by CT or MR

          -  Adequate hematologic function (Blood Counts)

          -  Adequate liver functions (blood tests)

          -  ECOG performance Status 0 or 1

          -  Peripheral neuropathy must be =&lt; grade 1

          -  PSA obtained within 3 months of entry

        Exclusion Criteria:

          -  Prior history of malignancy that are &lt; 5 years except for cancers found to be
             &quot;in-situ&quot; and would not likely impact a patient's life expectancy with appropriate
             medical management.

          -  Prior pelvic radiation therapy

          -  Prior hormonal therapy (up to 4 weeks prior to enrollment allowed)

          -  Individuals unable to tolerate lying still 5 - 10 minutes

          -  Patients with a history of severe hypersensitivity reaction to docetaxel or other
             drugs formulated with polysorbate 90.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony V. D'Amico, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute and (Sanofi-Aventis Consortium)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2005</study_first_submitted>
  <study_first_submitted_qc>June 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2005</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Anthony V. D'Amico, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Hormone Refractory</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Localized</keyword>
  <keyword>Locally Advanced</keyword>
  <keyword>Prostate Cancer - High Risk Localized or Locally Advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

